Stryker (SYK) Stock May Trade At A Discount Despite FDA Clearance

Stryker has had a mixed run, with the share price up 22.3% over three years but still showing declines over the past year. This puts fresh focus on whether the current US$307.08 level lines up with the cash the business can generate. With new products, fresh partnerships and legal scrutiny all in play, the question for anyone looking at the stock is how those moving parts feed into its underlying cash flow story.

• The 22.3% gain over three years means a holder today is looking at a stock where past returns already embed a meaningful view on Stryker’s future cash generation.

• Recent FDA clearance for the Sonopet 3 system and the US$400 million commitment to CMR Surgical may support expectations for future surgical revenue, but they also shape when and how much cash comes back relative to the outlay.

• What if you looked at Stryker through its earnings instead? See why Stryker’s 31.6x P/E tells a different valuation story.

The stock’s next move may depend on whether the current price can be explained by the cash flows implied by the Discounted Cash Flow (DCF) intrinsic value estimate.

For a wider lens on this kind of cash flow driven story, compare Stryker with other medical and surgical names using the 36 healthcare AI stocks.

Does Stryker Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Stryker can generate for shareholders and discounts it back to today. On this view, the latest twelve month free cash flow of about $4.7b sits alongside projections that assume free cash flow keeps growing from current levels rather than shrinking or swinging sharply.

Those projections, combined with the current share price of $307.08, lead to an estimated intrinsic value that the model places meaningfully above where the stock trades today. The recent Pomerantz investigation into potential securities issues helps explain why the market may still be pricing Stryker below what its projected cash generation implies, even as management continues to invest in areas like surgical robotics. Find out what Stryker could be worth using our Discounted Cash Flow (DCF) estimate.

The Stryker Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives pick up where the DCF puzzle for Stryker leaves off by explaining which expectations for Stryker’s growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each narrative presents fair value as a thesis about how the business might develop that readers can revisit over time to see how that view holds up against new information.